Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Functional food regulation

This article was originally published in The Tan Sheet

Executive Summary

FDA should implement GAO's recommendations for regulation of functional foods, including establishing "advisory committee to reevaluate the current labeling approaches for foods with novel ingredients," Center for Science in the Public Interest say in a March 21 citizen petition. Premarket notification of novel functional food ingredients is warranted because FDA "needs to determine whether instructions for use are required and whether the manufacturer needs to specify" how often food should be consumed, CSPI says. GAO report, issued July 2000, also suggested Congress amend the FD&C Act to harmonize dietary supplement, functional food standards (1"The Tan Sheet" July 17, 2000, p. 14)...

You may also be interested in...



Dietary Supplement, Functional Food Regulatory Harmonization Urged By GAO

Congress should amend the FD&C Act to require that functional foods meet the same regulatory standards that dietary supplements meet, the General Accounting Office recommends in a July 11 report.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel